 |
 |
Publications The following publications highlight HistoRx’s AQUA® quantitative tissue analysis technology: Breast Cancer Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B. Bimodal population or pathologist artifact? J Clin Oncol. 2007 Jun 10;25(17):2487-8. Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007:25:1, 19 - 26 Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL Quantitative analysis of estrogen receptor heterogeneity
in breast cancer Laboratory Investigation 10.1038/labinvest.3700543, March 5, 2007 Pozner-Moulis S, Cregger M, Camp RL, Rimm DL Antibody validation by quantitative analysis of protein
expression using expression of Met in breast cancer
as a model Laboratory Invetigation (2007) 1-10 0023-6837/07, January 29, 2007 Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL Classification of Breast Cancer Using Genetic Algorithms and Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In Situ Analysis of Beta-Catenin Expression in Breast Cancer Shows Decreased Expression is Associated With Poor Outcome. Cancer Research, 66(10): 5487-5494, May 15, 2006. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. Journal of the National Cancer Institute 97(24): 1808-1815, December 21, 2005. Siddiqui S, Pawelek J, Handerson T, Lin C-Y, Dickson RB, Rimm DL, Camp RL. Coexpression of Beta-1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome. Cancer Epidemiology Biomarkers & Prevention14(11): 2517-2523, November, 2005. Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated With Clinically Aggressive Disease. Cancer Research 65: 5578-5587, July 1, 2005. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 11(14): 5188-5194, June 15, 2005. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases is Predictive of Survival in Invasive Ductal Breast Cancer. Clinical Cancer Research 11: 4083-4089, June 1, 2005. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clinical Cancer Research 10: 7252-7259, November 1, 2004. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-Term Preservation of Antigenicity on Tissue Microarrays. Laboratory Investigation 84(8): 1071-1078, June 14, 2004. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome. Cancer Research 63: 1445-1448, April 1, 2003. Colon Cancer
Gastric Cancer Kidd, M. Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The Role of Genetic Markers—NAP1L1, MAGE-D2, and MTA1—In Defining Small-Intestinal Carcinoid Neoplasia. Annals of Surgical Oncology 13(2): 253-262, 2006. Kidd M, Modlin IM, Mane SM, Camp RL, Eick GN, Latich I, Zikusoka MN. Utility of Molecular Genetic Signatures in the Delineation of Gastric Neoplasia. Cancer 106(7):1480-1488, April 1, 2006. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite Instability and Gene Mutations in Transforming Growth Factor-Beta Type II Receptor are Absent in Small Bowel Carcinoid Tumors. Cancer 103(2): 229-236, January 15, 2005. Head and Neck Cancer Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis. Journal of Clinical Oncology 24(5): 736-747, February 10, 2006. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 11(16): 5856-5862, August 15, 2005. Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Beta-Catenin Functions Mainly as an Adhesion Molecule in Patients With Squamous Cell Cancer of the Head and Neck. Clinical Cancer Research 11: 2471-2477, April 1, 2005. Yu Z, Weinberger PM, Haffty BG, Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin D1 is a Valuable Prognostic Marker in Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research 11:1160-1166, February 1, 2005. Lung Cancer Gazdar AF. DNA repair and survival in lung cancer--the two faces of Janus. New England Journal of Medicine.356(8):771-3, February 22, 2007 Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. New England Journal of Medicine 356(8):800-8, February 22, 2007. Giltnane JM, Murren JR, Rimm DL, King BL. AQUA and FISH Analysis of HER-2/Neu Expression and Amplification in a Small Cell Lung Carcinoma Tissue Microarray. Histopathology 49: 161-169, 2006. Melanoma Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated
Protein Kinase Signaling Shows a New Type of Melanoma Cancer Research 67(4): 1502-1512, February 15, 2007 Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G The X-linked Inhibitor of Apoptosis Protein (XIAP) is Up-regulated
in Metastatic Melanoma, and XIAP Cleavage by Phenoxodiol is
Associated with Carboplatin Sensitization Journal of Translational Medicine 2007, 5:6 10.1186/1479-5876-5-6, January 26, 2007 McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. Clinical Cancer Research 12(12): 3856-3863, June 15, 2006. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated Quantitative Analysis of Activator Protein-2-Alpha Subcellular Expression In Melanoma Tissue Microarrays Correlates With Survival Prediction. Cancer Research 65(23):11185-11192, December 1, 2005. Merlino G. Cancer biology: the weakest link? Nature. 2005 Jul 7;436(7047):33-5. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma. Nature 436: 117-122, July 7, 2005. DiVito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated Quantitative Analysis of Tissue Microarrays Reveals an Association Between High Bcl-2 Expression and Improved Outcome in Melanoma. Cancer Research 64: 8773-8777, December 1, 2004. Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association With Early-Stage Disease and Improved Outcome. Cancer Research 64: 8767-8772, December 1, 2004. Ovarian Cancer Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economopoulos T, Dimopoulos MA Analysis of p53 Protein Expression Levels on Ovarian
Cancer Tissue Microarray using Automated Quantitative
Analysis Elucidates Prognostic Patient Subsets Annals of Oncology 10.1093/annonc/mdl479, January 13, 2007 Bamias A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulus MA, Psyrri A. Automated Quantitative Analysis of DCC Tumor Suppressor Protein in Ovarian Cancer Tissue Microarray shows Association with β-catenin Levels and Outcome in Patients with Epithelial Ovarian Cancer. Annals of Oncology 10.1093/annonc/mdl310, September 13, 2006. Psyrri A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D,
Camp RL, Rimm DL, Dimopoulos MA. Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. Cancer Epidemiology Biomarkers & Prevention15(6): 1179-1183, June, 2006. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients With Epithelial Ovarian Cancer. Clinical Cancer Research 11(24): 8637-8643, December 15, 2005. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor P27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 11(23): 8384-8390, December 1, 2005. Pancreatic Cancer Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular Endothelial Growth Factor, FLT-1, and FLK-1 Analysis in a Pancreatic Cancer Tissue Microarray. Cancer 106(8): 1677-1684, April 15, 2006. Prostate Cancer Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL. Quantitative Determination of Expression of the Prostate Cancer Protein alpha-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA). American Journal of Pathology 164(3): 831-840, March, 2004. Renal Cell Cancer Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, Rubin MA Automated immunofluorescence analysis defines
microvessel area as a prognostic parameter in
clear cell renal cell cancer Human Pathology 2007 38, 1454-1462 Methods & Reviews Rimm, DL. What Brown Cannot Do for You. [Commentary.] Nature Biotechnology 24(8): 914-916, August, 2006. Dolled-Filhart MP, Rimm DL, Stroobant P. [Review.] Quantitative In Situ Cancer Proteomics: Molecular Pathology Comes of Age With Automated Tissue Microarray Analysis. Personalized Medicine 2(4): 291-300, 2005. Henson DE. Back to the Drawing Board on Immunohistochemistry and Predictive Factors. [Editorial.] Journal of the National Cancer Institute 97(24): 1796-1797, December 21, 2005. Chiriboga L, Osman I, Mikhail M, Lau C. [Letter to the Editor.] Tissue Microarrays, Tread Carefully. Laboratory Investigation 84: 1677, April, 2004. Other Therapeutic Areas Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, Perlee LT, Quezado M, Spollen LE, Wustman BA, Schiffmann R Cellular and tissue localization of globotriaosylceramide
in Fabry disease Springer. Virchows Arch DOI 10.1007/s00428-007-0468-6
 |
|||||
|
300 George Street New Haven, CT 06511 |
P: 203 498 7500 |
F: 203 498 7501 |
E: info@historx.com © 2005 HistoRx.com |
|||||
Camp RL, Chung GG, Rimm DL. Automated Subcellular Localization and Quantification of Protein Expression in Tissue Microarrays. Nature Medicine 8(11): 1323-1327, November, 2002. 
